Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the trad ...

Core Viewpoint - Exelixis (EXEL) shows a significantly improving earnings outlook, making it a solid investment choice as analysts continue to raise their earnings estimates for the company [1][2]. Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Exelixis's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, Exelixis is projected to earn $0.46 per share, reflecting a 39.39% increase from the previous year, with a 14.31% rise in the Zacks Consensus Estimate over the last 30 days [4]. - For the full year, the earnings estimate stands at $1.92 per share, representing a 113.33% increase from the prior year, with a 5.73% increase in the consensus estimate due to nine upward revisions against one downward revision [5]. Zacks Rank - Exelixis currently holds a Zacks Rank 2 (Buy), supported by favorable estimate revisions, indicating strong potential for outperformance compared to the S&P 500 [6]. - Historically, Zacks 1 (Strong Buy) and 2 (Buy) ranked stocks have shown significant outperformance, with Zacks 1 stocks averaging a 25% annual return since 2008 [3][6]. Stock Performance - Exelixis shares have increased by 30.3% over the past four weeks, suggesting strong investor confidence in the company's earnings growth prospects [7].

Since my January 2024 article, Exelixis, Inc. (NASDAQ: EXEL ) has appreciated significantly. I believe this has been mostly due to Cabometyx’s continued success and its pipeline’s strategic progress. EXEL aims to become a genitourinary [GU] and gastrointestinal [GI] oncology leader. Its leading product is Cabometyx, aMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer scie ...

Core Insights - Exelixis, Inc. (EXEL) reported better-than-expected third-quarter results, with shares rising post-announcement [1][2] - The company recorded earnings of 47 cents per share, surpassing the Zacks Consensus Estimate of 42 cents, driven by higher revenues and lower operating expenses [1][2] - Net revenues reached $539.5 million, exceeding the Zacks Consensus Estimate of $491 million, marking a 14.3% year-over-year increase [2] Financial Performance - Net product revenues were $478 million, reflecting a 12.1% year-over-year increase, primarily due to higher sales volume and average net selling price [4] - Cabometyx generated revenues of $475.7 million, beating both the Zacks Consensus Estimate of $439 million and the model estimate of $434.6 million, with a 9% year-over-year growth in prescription volume [5] - Collaboration revenues totaled $61.5 million, up from $45.4 million in the year-ago quarter, driven by increased milestone-related revenues and higher royalty revenues from cabozantinib sales [6] Expense Management - Research and development expenses decreased to $222.6 million, down 33.1% year over year, mainly due to reduced license and collaboration costs [7] - Selling, general and administrative expenses totaled $111.8 million, down 19% year over year, attributed to declines in corporate giving, stock-based compensation, and legal fees [7] Stock Repurchase and Regulatory Updates - The board authorized a stock repurchase of up to $500 million, with $12.4 million repurchased at an average price of $25.61 per share as of September 30, 2024 [8] - Exelixis won a patent litigation case against MSN Laboratories regarding cabozantinib, with the court ruling in favor of Exelixis [9] Pipeline Developments - Management is focused on expanding the label for Cabometyx, with a supplemental new drug application accepted by the FDA for advanced pancreatic NET and extra-pancreatic NET [11] - An sNDA will be submitted for cabozantinib in combination with Tecentriq for metastatic castration-resistant prostate cancer [12] - Enrollment is complete for the STELLAR-303 study evaluating zanzalintinib in combination with Tecentriq for metastatic colorectal cancer, with preliminary results expected in 2025 [13] Revenue Guidance - Total revenues for 2024 are projected between $2.150 billion and $2.2 billion, an increase from previous guidance of $1.975-$2.075 billion [16] - Product revenues are estimated to be in the range of $1.775 billion to $1.825 billion, up from previous guidance of $1.65-$1.75 billion [16] - Research and development expenses are now estimated at $925-$950 million, while selling, general and administrative expenses are projected at $475-$500 million [17] Overall Assessment - Exelixis' third-quarter performance was strong, with both top and bottom lines exceeding estimates, and Cabometyx remains a leading TKI for RCC in the U.S. [18] - The potential label expansion for Cabometyx is expected to boost sales, and the increase in annual guidance is viewed positively [18]

TUESDAY, OCTOBER 29, 2024 Third Quarter 2024 Financial Results Nasdaq: EXEL EXELIXIS® Today's Agenda Introduction Varant Shirvanian Director, Investor Relations Business Update and Q3 2024 Highlights Michael M. Morrissey, Ph.D. President and CEO Financial Results & Guidance Chris Senner EVP and CFO Commercial Update PJ Haley EVP, Commercial Q&A All, joined by: Amy Peterson, M.D. EVP, Product Development and Medical Affairs and CMO Dana T. Aftab, Ph.D. EVP, Discovery and Translational Research and CSO 2 Safe ...

Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director, IR Michael Morrissey - President & CEO Christopher Senner - EVP & CFO Amy Peterson - EVP, Product Development, Medical Affairs & Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - EVP, Commercial Conference Call Participants Asthika Goonewardene - Truist Chi Fong - Bank of America Silvan Tuerkcan - Citizens JMP Michael Schmidt - Guggenheim Securit ...

Core Insights - Exelixis reported $539.54 million in revenue for Q3 2024, a 14.3% year-over-year increase, with an EPS of $0.47 compared to $0.10 a year ago, exceeding both revenue and EPS consensus estimates [1][3] Revenue Performance - Net product revenue was $478.06 million, surpassing the average estimate of $443.69 million by 10 analysts, reflecting a 12.1% increase year-over-year [3] - CABOMETYX generated $475.70 million in revenue, exceeding the seven-analyst average estimate of $438.54 million [3] - COMETRIQ revenue was $2.40 million, falling short of the $4.32 million estimate from seven analysts [3] - License revenue reached $60.24 million, significantly above the four-analyst average estimate of $42.11 million, marking a 42.2% year-over-year increase [3] - Collaboration services revenue was $1.24 million, below the $3.17 million average estimate from three analysts, representing a 59.3% decline year-over-year [3] Stock Performance - Exelixis shares have returned +9.8% over the past month, outperforming the Zacks S&P 500 composite's +1.7% change, with a Zacks Rank 2 (Buy) indicating potential for further outperformance [4]

Exelixis (EXEL) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 11.90%. A quarter ago, it was expected that this drug developer would post earnings of $0.37 per share when it actually produced earnings of $0.84, delivering a surprise of 127.03%. Over the last four quarters, the compan ...

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 - - Increasing Total Revenues and Net Product Revenue ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...